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importance of appropriate imputation and how determining the
mechanism of missing data informs the appropriate imputation
method. A probit model using missing data dummies can effec-
tively identify the mechanism of missing data and inform the
appropriate method for imputation.
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Project a large-scale, patient longitudinal database to the U.S.
insured population. The AHRQ Medical Expenditures Panel
Survey (MEPS) was used as the basis for the adjustment meth-
odology. MEPS are a source of data representing the cost and use
of health insurance coverage, and are comprised of several large
scale surveys of families, individuals, employers, and health care
providers. First, we subset the data source to the study popula-
tion, then used multivariate logistic regression to construct
demographics and case-mix based weights that were applied to
make the data similar to the national sample. The weight is
derived using inverse of probability of existing in the database.
To validate the weights, we randomly divided MEPS data into
two parts; training set, and validating set. We used the training
set to estimate the weights, then validated weights comparing
standardized differences in terms of demographics and health
status between the weighted and validating data sets. The fol-
lowing variables were used in the logistic regression: age group,
gender, race, location, income levels and health status (Charlson
Comorbidity Index and Chronic Conditions). i3 data were more
likely to be male, older, chronic, and white (p = 0.0000).
Adjusted weight values for the Commercial group ranged from 1
to 51 with median 1.63, Medicaid 1 to 104 with median 1.03,
and Medicare 1 to 61 with median 1.07. After applying adjusted
weights, standardized differences in all confounders were less
than 105. National projection of a large-scale, patient longitudi-
nal database requires adjustment from not only demographic
factors but also case-mix differences related to health status. The
created weights successfully balanced the population in terms of
co-morbid conditions and chronic conditions as well as demo-
graphic factors.
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OBJECTIVES: Prescription drug studies using large administra-
tive databases usually require that NDCs be converted to generic
or therapeutic categories for analysis because NDCs are struc-
tured with this information. Commercial crosswalk solutions for
assigning generic and therapeutic codes to NDCs are available,
but they are generally designed for applications other just con-
verting NDCs. The cost of these comprehensive systems can be
prohibitive for academic researchers conducting small to medium
size projects; thus limiting research possibilities. A new system
for making this conversion has been devised. METHODS:
Because this system is designed solely for the purpose of convert-
ing NDCs to generic and therapeutic categories, it does not have
many of the features found in commercially available systems
(e.g., counseling notes, drug-drug interactions, patient informa-
tion, etc.). However, advantages of the new system for academic
researchers are its ease of use, method of delivery, simplicity,
logical structure, comprehensive coverage, and free distribution.
RESULTS: The new system provides a crosswalk from NDCs to
generic entity and therapeutic category codes. Other selection
criteria include dosage form, strength, and route of administra-
tion. This SQL-based system is accessible by a point-and-click
user interface to select and download records of interest. Users
then match the selected codes by NDC to a claims database to
obtain the desired drug claims. Currently, the system includes
coding for over 25,000 NDCs at the nine digit level (11 digit
NDC without package size code). Additional NDCs will be
added as they are identiﬁed. CONCLUSION: Two capabilities of
this system, ability to aggregate drugs generically and therapeu-
tically, are not found in the FDA database. In addition, the new
system is retrospective whereas the FDA system is not. Academic
researchers have a new tool for research using large databases of
prescription claims.
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OBJECTIVE: To compare the sensitivity and timing of ADRs
signal early detection across the four DMAs based on the
Adverse Events Reporting System (AERS) of the Food and Drug
Administration. METHODS: The four DMAs,including the
Reporting Odds Ratio (ROR), the Proportional Reporting Ratio
(PRR), the Information Component (IC), and the Gamma
Poisson Shrinker (GPS), are applied to retrospectively detect ten
conﬁrmed drug events combinations (DECs). The sensitivity to
detect adverse events is deﬁned as the percentage of DECs that
are detected by the DMA as positive signals. The sensitivity of
each DMA given different number of reports per DEC is mea-
sured as well. The timing of ADRs signal early detection is
measured by comparing the index date of withdrawal (IDW)
with the index date of detection (IDD). The IDW is deﬁned as
the date on which the drug was removed from the market, while
the IDD is deﬁned as a date on which the signal is signiﬁcantly
detected by DMAs. RESULTS: The estimated sensitivity to
detect adverse drug event is 100% for the ROR, 90% for the
PRR and the IC, and 70% for the GPS. The difference is not
statistically signiﬁcant. The sensitivity increases while increasing
the number of reports per DEC. The average period of interval
between the IDD and the IDW per DEC are approximately 10.1
quarters for the ROR, 9 quarters for the PRR, 9.9 quarters for
the IC, and 4.7 quarters for the GPS, indicating the ROR is
associated with the earliest signal detection among four DMAs.
CONCLUSION: Given the overall consideration of the sensitiv-
ity and the timing of signal detection, ROR may be considered as
the ﬁrst choice when selecting DMAs to conduct ADRs signal
detection. The ﬁndings need to be further validated in a prospec-
tive context.
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